Table 2: Historical MIPS Quality Measure Benchmark Results; created using PY2019 data and PY2021 Eligibility Rules,,,,,,,,,,,,,,,,,
Measure_Name,Measure_ID,Collection_Type,Measure_Type,Benchmark,Standard_Deviation,Average,Decile_3,Decile_4,Decile_5,Decile_6,Decile_7,Decile_8,Decile_9,Decile_10,Topped_Out,Seven_Point_Cap,High_Priority
"Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use","93","Medicare Part B Claims","Process","Y","","","12.86 - 54.73","54.74 - 72.72","72.73 - 95.18","95.19 - 99.99","--","--","--","100.0","No","","Y"
"Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use","93","QCDR Measure","Process","Y","","","39.47 - 65.42","65.43 - 73.84","73.85 - 86.17","86.18 - 95.41","95.42 - 99.99","--","--","100.0","No","","Y"
"Breast Cancer Screening","112","Medicare Part B Claims","Process","Y","","","2.54 - 25.92","25.93 - 41.85","41.86 - 71.76","71.77 - 90.01","90.02 - 98.19","98.2 - 99.99","--","100.0","No","","N"
"Breast Cancer Screening","112","eCQM","Process","Y","","","0.32 - 2.79","2.8 - 9.22","9.23 - 30.84","30.85 - 54.62","54.63 - 71.12","71.13 - 83.32","83.33 - 89.68",">= 89.69","No","","N"
"Functional Status Change for Patients with Shoulder Impairments","221","QCDR Measure","patientReportedOutcome","Y","","","59.21 - 83.32","83.33 - 91.14","91.15 - 96.33","96.34 - 99.23","99.24 - 99.99","--","--","100.0","No","","Y"
"""Infection within 180 Days of Cardiac Implantable Electronic Device (CIED) Implantation, Replacement, or Revision""","393","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Risk-Adjusted Operative Mortality for Coronary Artery Bypass Graft (CABG)","445","QCDR Measure","Outcome","Y","","","12.17 - 6.68","6.67 - 5.01","5.0 - 3.1","3.09 - 1.48","1.47 - 0.01","--","--","0.0","No","","Y"
"Prevention of Post-Operative Vomiting (POV) – Combination Therapy (Pediatrics)","463","QCDR Measure","Process","Y","","","71.76 - 82.04","82.05 - 88.78","88.79 - 96.51","96.52 - 99.1","99.11 - 99.99","--","--","100.0","No","","Y"
"Preventive Care and Screening: Influenza Immunization","110","eCQM","Process","Y","","","0.21 - 2.63","2.64 - 9.67","9.68 - 27.95","27.96 - 49.48","49.49 - 73.6","73.61 - 94.69","94.7 - 99.37",">= 99.38","No","","N"
"Preventive Care and Screening: Influenza Immunization","110","Medicare Part B Claims","Process","Y","","","0.75 - 13.03","13.04 - 27.44","27.45 - 69.91","69.92 - 92.9","92.91 - 99.99","--","--","100.0","No","","N"
"Radiology: Inappropriate Use of “Probably Benign” Assessment Category in Screening Mammograms","146","Medicare Part B Claims","Process","Y","","","4.88 - 1.5","1.49 - 0.8","0.79 - 0.22","0.21 - 0.01","--","--","--","0.0","No","","Y"
"Radiology: Inappropriate Use of “Probably Benign” Assessment Category in Screening Mammograms","146","QCDR Measure","Process","Y","","","7.26 - 1.14","1.13 - 0.55","0.54 - 0.13","0.12 - 0.01","--","--","--","0.0","No","","Y"
"Falls: Plan of Care","155","Medicare Part B Claims","Process","Y","","","2.31 - 13.75","13.76 - 27.49","27.5 - 94.58","94.59 - 99.99","--","--","--","100.0","No","","Y"
"Falls: Plan of Care","155","QCDR Measure","Process","Y","","","2.08 - 20.78","20.79 - 57.44","57.45 - 90.96","90.97 - 99.99","--","--","--","100.0","No","","Y"
"Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure","167","QCDR Measure","Outcome","Y","","","6.52 - 5.25","5.24 - 4.3","4.29 - 2.68","2.67 - 1.53","1.52 - 0.68","0.67 - 0.01","--","0.0","No","","Y"
"Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration","168","QCDR Measure","Outcome","Y","","","12.12 - 9.77","9.76 - 7.28","7.27 - 3.12","3.11 - 1.56","1.55 - 0.01","--","--","0.0","No","","Y"
"""Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients""","324","QCDR Measure","Efficiency and Cost/Resource Use","Y","","","83.33 - 28.24","28.23 - 9.32","9.31 - 2.09","2.08 - 0.01","--","--","--","0.0","No","","Y"
"HIV Viral Load Suppression","338","QCDR Measure","Outcome","Y","","","2.86 - 33.99","34.0 - 58.32","58.33 - 84.08","84.09 - 92.85","92.86 - 99.99","--","--","100.0","No","","Y"
"Documentation of Current Medications in the Medical Record","130","eCQM","Process","Y","","","2.72 - 23.68","23.69 - 59.66","59.67 - 89.35","89.36 - 97.99","98.0 - 99.83","99.84 - 99.99","--","100.0","No","","Y"
"Documentation of Current Medications in the Medical Record","130","Medicare Part B Claims","Process","Y","","","10.52 - 85.83","85.84 - 97.38","97.39 - 99.84","99.85 - 99.99","--","--","--","100.0","No","","Y"
"Dementia Associated Behavioral and Psychiatric Symptoms Screening and Management","283","QCDR Measure","Process","Y","","","1.32 - 23.86","23.87 - 56.37","56.38 - 84.43","84.44 - 98.51","98.52 - 99.99","--","--","100.0","No","","N"
"Closing the Referral Loop: Receipt of Specialist Report","374","eCQM","Process","Y","","","0.34 - 2.08","2.09 - 4.43","4.44 - 14.11","14.12 - 37.97","37.98 - 73.01","73.02 - 95.96","95.97 - 99.99","100.0","No","","Y"
"Psoriasis: Clinical Response to Systemic Medications","410","QCDR Measure","Outcome","Y","","","4.76 - 19.68","19.69 - 36.1","36.11 - 64.09","64.1 - 87.99","88.0 - 99.99","--","--","100.0","No","","Y"
"Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older","415","QCDR Measure","Efficiency and Cost/Resource Use","Y","","","40.63 - 59.59","59.6 - 70.04","70.05 - 86.19","86.2 - 96.03","96.04 - 98.77","98.78 - 99.99","--","100.0","No","","Y"
"Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older","415","Medicare Part B Claims","Efficiency","Y","","","46.03 - 67.99","68.0 - 80.94","80.95 - 89.79","89.8 - 95.23","95.24 - 97.75","97.76 - 99.99","--","100.0","No","","Y"
"Proportion of Patients Sustaining a Bowel Injury at the time of any Pelvic Organ Prolapse Repair","433","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%)","1","Medicare Part B Claims","Intermediate Outcome","Y","","","89.39 - 54.15","54.14 - 34.86","34.85 - 16.01","16.0 - 8.76","8.75 - 4.36","4.35 - 1.8","1.79 - 0.01","0.0","No","","Y"
"Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%)","1","eCQM","Intermediate Outcome","Y","","","99.51 - 97.77","97.76 - 93.42","93.41 - 67.8","67.79 - 37.87","37.86 - 22.51","22.5 - 14.05","14.04 - 9.44","<= 9.43","No","","Y"
"Controlling High Blood Pressure","236","eCQM","Intermediate Outcome","Y","","","2.78 - 29.39","29.4 - 42.51","42.52 - 54.99","55.0 - 65.48","65.49 - 75.22","75.23 - 84.57","84.58 - 90.19",">= 90.2","No","","Y"
"Controlling High Blood Pressure","236","Medicare Part B Claims","Intermediate Outcome","Y","","","20.57 - 45.23","45.24 - 53.36","53.37 - 65.24","65.25 - 77.9","77.91 - 89.86","89.87 - 98.4","98.41 - 99.99","100.0","No","","Y"
"Unplanned Reoperation within the 30 Day Postoperative Period","355","QCDR Measure","Outcome","Y","","","58.39 - 13.16","13.15 - 5.34","5.33 - 1.89","1.88 - 0.01","--","--","--","0.0","No","","Y"
"Adherence to Antipsychotic Medications For Individuals with Schizophrenia","383","QCDR Measure","Intermediate Outcome","Y","","","0.75 - 6.44","6.45 - 33.99","34.0 - 76.79","76.8 - 99.99","--","--","--","100.0","No","","Y"
"Rate of Surgical Conversion from Lower Extremity Endovascular Revascularization Procedure","437","QCDR Measure","Outcome","Y","","","54.47 - 5.01","5.0 - 1.99","1.98 - 0.77","0.76 - 0.01","--","--","--","0.0","No","","Y"
"Rate of Surgical Conversion from Lower Extremity Endovascular Revascularization Procedure","437","Medicare Part B Claims","Outcome","Y","","","4.0 - 1.76","1.75 - 1.68","1.67 - 0.01","--","--","--","--","0.0","No","","Y"
"Statin Therapy for the Prevention and Treatment of Cardiovascular Disease","438","eCQM","Process","Y","","","5.43 - 44.88","44.89 - 55.46","55.47 - 65.02","65.03 - 71.73","71.74 - 78.14","78.15 - 84.08","84.09 - 87.79",">= 87.8","No","","N"
"Appropriate Workup Prior to Endometrial Ablation","448","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Hematology: Multiple Myeloma: Treatment with Bisphosphonates","69","QCDR Measure","Process","Y","","","5.71 - 9.51","9.52 - 23.63","23.64 - 46.14","46.15 - 75.85","75.86 - 86.35","86.36 - 99.99","--","100.0","No","","N"
"Melanoma: Continuity of Care – Recall System","137","QCDR Measure","Structure","Y","","","4.35 - 41.85","41.86 - 74.21","74.22 - 97.63","97.64 - 99.99","--","--","--","100.0","No","","Y"
"Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents","239","eCQM","Process","Y","","","0.57 - 13.77","13.78 - 21.52","21.53 - 29.13","29.14 - 33.32","33.33 - 42.65","42.66 - 63.1","63.11 - 76.63",">= 76.64","No","","N"
"Sleep Apnea: Assessment of Adherence to Positive Airway Pressure Therapy","279","QCDR Measure","Process","Y","","","0.23 - 12.49","12.5 - 67.49","67.5 - 92.11","92.12 - 99.99","--","--","--","100.0","No","","N"
"Pain Brought Under Control Within 48 Hours","342","QCDR Measure","Outcome","Y","","","32.56 - 84.48","84.49 - 99.99","--","--","--","--","--","100.0","No","","Y"
"Functional Status Assessment for Total Hip Replacement","376","eCQM","Process","Y","","","0.23 - 0.88","0.89 - 1.73","1.74 - 6.72","6.73 - 15.82","15.83 - 41.01","41.02 - 99.99","--","100.0","No","","Y"
"Functional Status Assessments for Congestive Heart Failure","377","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Osteoporosis Management in Women Who Had a Fracture","418","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older","48","Medicare Part B Claims","Process","Y","","","0.33 - 1.67","1.68 - 4.54","4.55 - 93.12","93.13 - 99.99","--","--","--","100.0","No","","N"
"Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older","48","QCDR Measure","Process","Y","","","0.49 - 3.32","3.33 - 8.0","8.01 - 31.66","31.67 - 71.59","71.6 - 95.57","95.58 - 99.99","--","100.0","No","","N"
"Initiation and Engagement of Alcohol and Other Drug Dependence Treatment","305","eCQM","Process","Y","","","0.03 - 0.09","0.1 - 0.14","0.15 - 0.32","0.33 - 0.9","0.91 - 2.23","2.24 - 7.77","7.78 - 15.99",">= 16.0","No","","Y"
"Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the Operating Room Within 90 Days of Surgery","384","QCDR Measure","Outcome","Y","","","62.96 - 70.82","70.83 - 82.6","82.61 - 98.35","98.36 - 99.99","--","--","--","100.0","No","","Y"
"Ischemic Vascular Disease (IVD) All or None Outcome Measure (Optimal Control)","441","QCDR Measure","Intermediate Outcome","Y","","","0.41 - 3.47","3.48 - 5.5","5.51 - 18.07","18.08 - 36.81","36.82 - 52.75","52.76 - 64.0","64.01 - 73.52",">= 73.53","No","","Y"
"Medication Management for People with Asthma","444","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Functional Status Change for Patients with Knee Impairments","217","QCDR Measure","patientReportedOutcome","Y","","","16.74 - 63.63","63.64 - 87.9","87.91 - 96.29","96.3 - 99.52","99.53 - 99.99","--","--","100.0","No","","Y"
"Parkinson’s Disease: Psychiatric Symptoms Assessment for Patients with Parkinson’s Disease","290","QCDR Measure","Process","Y","","","1.75 - 3.13","3.14 - 18.37","18.38 - 46.76","46.77 - 91.95","91.96 - 99.99","--","--","100.0","No","","N"
"Parkinson’s Disease: Rehabilitative Therapy Options","293","QCDR Measure","Process","Y","","","0.4 - 1.81","1.82 - 3.79","3.8 - 58.44","58.45 - 92.97","92.98 - 99.99","--","--","100.0","No","","Y"
"Clinical Outcome Post Endovascular Stroke Treatment","409","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Radiology: Reminder System for Screening Mammograms","225","Medicare Part B Claims","Structure","Y","","","8.86 - 86.73","86.74 - 99.47","99.48 - 99.99","--","--","--","--","100.0","No","","Y"
"Radiology: Reminder System for Screening Mammograms","225","QCDR Measure","Structure","Y","","","24.05 - 99.83","99.84 - 99.99","--","--","--","--","--","100.0","No","","Y"
"Rate of Open Repair of Small or Moderate Non-Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7)","258","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Adult Primary Rhegmatogenous Retinal Detachment Surgery: Visual Acuity Improvement Within 90 Days of Surgery","385","QCDR Measure","Outcome","Y","","","10.11 - 20.96","20.97 - 23.67","23.68 - 46.87","46.88 - 58.27","58.28 - 74.62","74.63 - 85.18","85.19 - 99.99","100.0","No","","Y"
"Performing Cystoscopy at the Time of Hysterectomy for Pelvic Organ Prolapse to Detect Lower Urinary Tract Injury","422","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Functional Status After Lumbar Fusion","469","","patientReportedOutcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Appropriate Use of DXA Scans in Women Under 65 Years Who Do Not Meet the Risk Factor Profile for Osteoporotic Fracture","472","eCQM","Process","Y","","","29.01 - 3.93","3.92 - 0.01","--","--","--","--","--","0.0","No","","Y"
"Anti-Depressant Medication Management","9","eCQM","Process","Y","","","9.09 - 37.49","37.5 - 55.01","55.02 - 67.99","68.0 - 78.14","78.15 - 84.99","85.0 - 90.27","90.28 - 93.8",">= 93.81","No","","N"
"Colorectal Cancer Screening","113","Medicare Part B Claims","Process","Y","","","4.4 - 21.74","21.75 - 38.38","38.39 - 71.13","71.14 - 92.01","92.02 - 99.99","--","--","100.0","No","","N"
"Colorectal Cancer Screening","113","eCQM","Process","Y","","","0.13 - 0.81","0.82 - 3.24","3.25 - 21.6","21.61 - 49.98","49.99 - 72.91","72.92 - 86.0","86.01 - 91.99",">= 92.0","No","","N"
"Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)","118","QCDR Measure","Process","Y","","","31.85 - 59.2","59.21 - 67.57","67.58 - 75.12","75.13 - 82.1","82.11 - 88.48","88.49 - 96.73","96.74 - 99.99","100.0","No","","N"
"Stroke and Stroke Rehabilitation: Thrombolytic Therapy","187","QCDR Measure","Process","Y","","","31.82 - 60.86","60.87 - 71.99","72.0 - 85.7","85.71 - 93.54","93.55 - 99.99","--","--","100.0","No","","N"
"Childhood Immunization Status","240","eCQM","Process","Y","","","1.11 - 5.79","5.8 - 9.51","9.52 - 21.62","21.63 - 36.35","36.36 - 46.78","46.79 - 56.68","56.69 - 61.39",">= 61.4","No","","N"
"Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy","268","QCDR Measure","Process","Y","","","0.18 - 3.44","3.45 - 8.32","8.33 - 23.99","24.0 - 54.02","54.03 - 94.94","94.95 - 99.99","--","100.0","No","","N"
"Maternity Care: Postpartum Follow-up and Care Coordination","336","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Total Knee Replacement: Shared Decision-Making: Trial of Conservative (Non-surgical) Therapy","350","QCDR Measure","Process","Y","","","2.63 - 71.5","71.51 - 90.55","90.56 - 99.99","--","--","--","--","100.0","No","","Y"
"Follow-Up Care for Children Prescribed ADHD Medication (ADD)","366","eCQM","Process","Y","","","1.86 - 8.99","9.0 - 13.98","13.99 - 22.49","22.5 - 35.9","35.91 - 47.65","47.66 - 62.66","62.67 - 76.69",">= 76.7","No","","N"
"Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients","406","Medicare Part B Claims","Process","Y","","","61.9 - 24.01","24.0 - 5.01","5.0 - 0.01","--","--","--","--","0.0","No","","Y"
"Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients","406","QCDR Measure","Process","Y","","","50.0 - 30.01","30.0 - 11.4","11.39 - 0.69","0.68 - 0.01","--","--","--","0.0","No","","Y"
"Evaluation or Interview for Risk of Opioid Misuse","414","QCDR Measure","Process","Y","","","0.87 - 22.78","22.79 - 66.12","66.13 - 97.38","97.39 - 99.99","--","--","--","100.0","No","","Y"
"Varicose Vein Treatment with Saphenous Ablation: Outcome Survey","420","","patientReportedOutcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Prevention of Post-Operative Nausea and Vomiting (PONV) – Combination Therapy","430","QCDR Measure","Process","Y","","","56.21 - 80.39","80.4 - 92.81","92.82 - 97.62","97.63 - 99.47","99.48 - 99.96","99.97 - 99.99","--","100.0","No","","Y"
"Uterine Artery Embolization Technique: Documentation of Angiographic Endpoints and Interrogation of Ovarian Arteries","465","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Age-Related Macular Degeneration (AMD): Dilated Macular Examination","14","QCDR Measure","Process","Y","","","7.32 - 45.82","45.83 - 70.67","70.68 - 89.88","89.89 - 97.0","97.01 - 99.95","99.96 - 99.99","--","100.0","No","","N"
"Age-Related Macular Degeneration (AMD): Dilated Macular Examination","14","Medicare Part B Claims","Process","Y","","","30.43 - 87.63","87.64 - 96.24","96.25 - 99.99","--","--","--","--","100.0","No","","N"
"Oncology: Medical and Radiation - Plan of Care for Pain","144","QCDR Measure","Process","Y","","","4.88 - 33.32","33.33 - 51.23","51.24 - 77.26","77.27 - 96.91","96.92 - 99.99","--","--","100.0","No","","Y"
"Tuberculosis Screening Prior to First Course Biologic Therapy","176","QCDR Measure","Process","Y","","","2.52 - 12.95","12.96 - 27.77","27.78 - 70.48","70.49 - 93.66","93.67 - 99.99","--","--","100.0","No","","N"
"Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity","177","QCDR Measure","Process","Y","","","0.73 - 11.2","11.21 - 41.97","41.98 - 72.51","72.52 - 91.11","91.12 - 99.05","99.06 - 99.99","--","100.0","No","","N"
"Functional Outcome Assessment","182","Medicare Part B Claims","Process","Y","","","12.95 - 80.36","80.37 - 97.09","97.1 - 99.79","99.8 - 99.99","--","--","--","100.0","No","","Y"
"Functional Outcome Assessment","182","QCDR Measure","Process","Y","","","0.08 - 3.21","3.22 - 84.43","84.44 - 98.87","98.88 - 99.94","99.95 - 99.99","--","--","100.0","No","","Y"
"""Functional Status Change for Patients with Elbow, Wrist or Hand Impairments""","222","QCDR Measure","patientReportedOutcome","Y","","","35.16 - 76.27","76.28 - 85.92","85.93 - 96.64","96.65 - 99.99","--","--","--","100.0","No","","Y"
"Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented","317","eCQM","Process","Y","","","0.21 - 5.81","5.82 - 13.61","13.62 - 23.87","23.88 - 34.86","34.87 - 49.11","49.12 - 73.99","74.0 - 97.41",">= 97.42","No","","N"
"Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented","317","Medicare Part B Claims","Process","Y","","","1.21 - 23.65","23.66 - 50.64","50.65 - 96.6","96.61 - 99.99","--","--","--","100.0","No","","N"
"Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy","326","Medicare Part B Claims","Process","Y","","","50.0 - 84.99","85.0 - 93.17","93.18 - 99.85","99.86 - 99.99","--","--","--","100.0","No","","N"
"Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy","326","QCDR Measure","Process","Y","","","14.15 - 57.01","57.02 - 69.61","69.62 - 81.67","81.68 - 94.51","94.52 - 99.99","--","--","100.0","No","","N"
"""Rate of Carotid Artery Stenting (CAS) for Asymptomatic Patients, Without Major Complications (Discharged to Home by Post-Operative Day #2)""","344","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Optimal Asthma Control","398","QCDR Measure","Outcome","Y","","","0.44 - 9.37","9.38 - 23.22","23.23 - 46.75","46.76 - 80.13","80.14 - 99.99","--","--","100.0","No","","Y"
"One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk","400","QCDR Measure","Process","Y","","","0.12 - 0.25","0.26 - 0.53","0.54 - 1.66","1.67 - 8.58","8.59 - 35.81","35.82 - 75.52","75.53 - 94.96",">= 94.97","No","","N"
"Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)","5","eCQM","Process","Y","","","5.7 - 48.97","48.98 - 61.53","61.54 - 75.46","75.47 - 87.09","87.1 - 99.43","99.44 - 99.99","--","100.0","No","","N"
"Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)","23","Medicare Part B Claims","Process","Y","","","0.82 - 27.49","27.5 - 96.29","96.3 - 99.99","--","--","--","--","100.0","No","","Y"
"Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)","23","QCDR Measure","Process","Y","","","1.14 - 10.19","10.2 - 36.13","36.14 - 98.61","98.62 - 99.99","--","--","--","100.0","No","","Y"
"Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery","44","QCDR Measure","Process","Y","","","56.34 - 77.32","77.33 - 86.63","86.64 - 95.82","95.83 - 99.99","--","--","--","100.0","No","","N"
"Preventive Care and Screening: Screening for Depression and Follow-Up Plan","134","eCQM","Process","Y","","","0.07 - 0.59","0.6 - 2.18","2.19 - 12.12","12.13 - 38.66","38.67 - 72.99","73.0 - 94.12","94.13 - 98.63",">= 98.64","No","","N"
"Preventive Care and Screening: Screening for Depression and Follow-Up Plan","134","Medicare Part B Claims","Process","Y","","","0.26 - 1.04","1.05 - 60.03","60.04 - 98.75","98.76 - 99.99","--","--","--","100.0","No","","N"
"Dementia: Functional Status Assessment","282","QCDR Measure","Process","Y","","","0.56 - 2.16","2.17 - 4.51","4.52 - 61.96","61.97 - 98.9","98.91 - 99.99","--","--","100.0","No","","N"
"Dementia: Safety Concern Screening and Follow-Up for Patients with Dementia","286","QCDR Measure","Process","Y","","","1.15 - 21.66","21.67 - 63.02","63.03 - 90.4","90.41 - 99.99","--","--","--","100.0","No","","Y"
"Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients","320","QCDR Measure","Process","Y","","","2.53 - 13.83","13.84 - 55.99","56.0 - 87.11","87.12 - 96.32","96.33 - 99.55","99.56 - 99.99","--","100.0","No","","Y"
"Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients","320","Medicare Part B Claims","Process","Y","","","5.61 - 33.32","33.33 - 84.99","85.0 - 96.76","96.77 - 99.99","--","--","--","100.0","No","","Y"
"Patient-Centered Surgical Risk Assessment and Communication","358","QCDR Measure","Process","Y","","","0.6 - 1.99","2.0 - 10.43","10.44 - 53.56","53.57 - 98.29","98.3 - 99.99","--","--","100.0","No","","Y"
"Perioperative Temperature Management","424","QCDR Measure","Outcome","Y","","","64.57 - 88.3","88.31 - 94.28","94.29 - 98.92","98.93 - 99.84","99.85 - 99.99","--","--","100.0","No","","Y"
"Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan","128","eCQM","Process","Y","","","3.85 - 15.48","15.49 - 19.23","19.24 - 26.49","26.51 - 47.89","47.9 - 86.23","86.24 - 98.52","98.53 - 99.99","100.0","No","","N"
"Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan","128","Medicare Part B Claims","Process","Y","","","17.98 - 38.32","38.33 - 61.69","61.7 - 96.45","96.46 - 99.99","--","--","--","100.0","No","","N"
"Barrett’s Esophagus","249","QCDR Measure","Process","Y","","","69.7 - 98.46","98.47 - 99.99","--","--","--","--","--","100.0","No","","N"
"Barrett’s Esophagus","249","Medicare Part B Claims","Process","Y","","","96.33 - 99.99","--","--","--","--","--","--","100.0","No","","N"
"Surgical Site Infection (SSI)","357","QCDR Measure","Outcome","Y","","","99.82 - 42.86","42.85 - 9.41","9.4 - 2.53","2.52 - 0.01","--","--","--","0.0","No","","Y"
"Optimizing Patient Exposure to Ionizing Radiation: Count of Potential High Dose Radiation Imaging Studies: Computed Tomography (CT) and Cardiac Nuclear Medicine Studies","360","QCDR Measure","Process","Y","","","0.01 - 11.33","11.34 - 30.26","30.27 - 94.42","94.43 - 99.99","--","--","--","100.0","No","","Y"
"Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment","382","eCQM","Process","Y","","","0.37 - 1.02","1.03 - 2.55","2.56 - 10.13","10.14 - 29.59","29.6 - 51.99","52.0 - 84.2","84.21 - 95.47",">= 95.48","No","","Y"
"Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 Through 17 Years","416","QCDR Measure","Efficiency and Cost/Resource Use","Y","","","84.62 - 62.71","62.7 - 45.63","45.62 - 24.63","24.62 - 5.98","5.97 - 1.28","1.27 - 0.01","--","0.0","No","","Y"
"Quality of Life Assessment For Patients With Primary Headache Disorders","435","QCDR Measure","patientReportedOutcome","Y","","","0.02 - 0.18","0.19 - 0.29","0.3 - 1.42","1.43 - 84.08","84.09 - 99.99","--","--","100.0","No","","Y"
"Age Appropriate Screening Colonoscopy","439","QCDR Measure","Efficiency and Cost/Resource Use","Y","","","89.9 - 89.75","89.74 - 80.51","80.5 - 26.84","26.83 - 0.01","--","--","--","0.0","No","","Y"
"Patients with Metastatic Colorectal Cancer and RAS (KRAS or NRAS) Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies","452","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Appropriate Treatment for Upper Respiratory Infection (URI)","65","eCQM","Process","Y","","","39.58 - 63.1","63.11 - 71.42","71.43 - 82.39","82.4 - 91.97","91.98 - 98.4","98.41 - 99.99","--","100.0","No","","Y"
"Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy","147","Medicare Part B Claims","Process","Y","","","8.89 - 26.18","26.19 - 42.58","42.59 - 79.99","80.0 - 97.95","97.96 - 99.99","--","--","100.0","No","","Y"
"Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy","147","QCDR Measure","Process","Y","","","25.84 - 63.63","63.64 - 80.91","80.92 - 97.49","97.5 - 99.99","--","--","--","100.0","No","","Y"
"Coronary Artery Bypass Graft (CABG): Prolonged Intubation","164","QCDR Measure","Outcome","Y","","","16.36 - 12.69","12.68 - 12.21","12.2 - 8.46","8.45 - 4.68","4.67 - 1.97","1.96 - 0.01","--","0.0","No","","Y"
"Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use","185","QCDR Measure","Process","Y","","","0.27 - 6.97","6.98 - 13.85","13.86 - 75.41","75.42 - 96.28","96.29 - 99.99","--","--","100.0","No","","Y"
"Sleep Apnea: Severity Assessment at Initial Diagnosis","277","QCDR Measure","Process","Y","","","1.45 - 2.48","2.49 - 5.43","5.44 - 31.38","31.39 - 74.85","74.86 - 99.99","--","--","100.0","No","","N"
"Cataract Surgery: Difference Between Planned and Final Refraction","389","QCDR Measure","Outcome","Y","","","3.07 - 10.83","10.84 - 18.74","18.75 - 34.32","34.33 - 68.88","68.89 - 99.11","99.12 - 99.99","--","100.0","No","","Y"
"Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques","436","QCDR Measure","Process","Y","","","4.19 - 84.66","84.67 - 95.24","95.25 - 99.52","99.53 - 99.99","--","--","--","100.0","No","","N"
"Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques","436","Medicare Part B Claims","Process","Y","","","0.52 - 51.47","51.48 - 81.45","81.46 - 97.71","97.72 - 99.85","99.86 - 99.99","--","--","100.0","No","","N"
"Percentage of Patients Who Died from Cancer Admitted to the Intensive Care Unit (ICU) in the Last 30 Days of Life (lower score – better)","455","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"All-cause Hospital Readmission","458","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Urinary Symptom Score Change 6-12 Months After Diagnosis of Benign Prostatic Hyperplasia","476","","patientReportedOutcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Coronary Artery Disease (CAD): Antiplatelet Therapy","6","QCDR Measure","Process","Y","","","30.89 - 59.9","59.91 - 68.72","68.73 - 80.07","80.08 - 89.99","90.0 - 97.12","97.13 - 99.99","--","100.0","No","","N"
"Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older","50","Medicare Part B Claims","Process","Y","","","2.9 - 70.76","70.77 - 91.17","91.18 - 99.69","99.7 - 99.99","--","--","--","100.0","No","","Y"
"Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older","50","QCDR Measure","Process","Y","","","1.49 - 9.88","9.89 - 26.91","26.92 - 69.41","69.42 - 91.15","91.16 - 99.99","--","--","100.0","No","","Y"
"Appropriate Testing for Pharyngitis","66","eCQM","Process","Y","","","3.28 - 19.99","20.0 - 47.21","47.22 - 75.18","75.19 - 89.22","89.23 - 99.46","99.47 - 99.99","--","100.0","No","","Y"
"Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care","141","QCDR Measure","Outcome","Y","","","0.11 - 3.82","3.83 - 14.7","14.71 - 46.83","46.84 - 93.65","93.66 - 99.99","--","--","100.0","No","","Y"
"Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care","141","Medicare Part B Claims","Outcome","Y","","","27.03 - 86.89","86.9 - 96.46","96.47 - 99.99","--","--","--","--","100.0","No","","Y"
"Radiology: Exposure Dose Indices or Exposure Time and Number of Images Reported for Procedures Using Fluoroscopy","145","QCDR Measure","Process","Y","","","2.7 - 28.23","28.24 - 61.29","61.3 - 91.85","91.86 - 99.87","99.88 - 99.99","--","--","100.0","No","","Y"
"Radiology: Exposure Dose Indices or Exposure Time and Number of Images Reported for Procedures Using Fluoroscopy","145","Medicare Part B Claims","Process","Y","","","2.6 - 25.92","25.93 - 62.28","62.29 - 91.48","91.49 - 99.18","99.19 - 99.99","--","--","100.0","No","","Y"
"Cardiac Rehabilitation Patient Referral from an Outpatient Setting","243","QCDR Measure","Process","Y","","","4.76 - 9.19","9.2 - 12.7","12.71 - 23.18","23.19 - 37.95","37.96 - 57.19","57.2 - 90.87","90.88 - 98.16",">= 98.17","No","","Y"
"Proportion of Patients Sustaining a Bladder Injury at the Time of any Pelvic Organ Prolapse Repair","432","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second-Generation Cephalosporin","21","QCDR Measure","Process","Y","","","0.49 - 2.16","2.17 - 11.08","11.09 - 89.33","89.34 - 99.99","--","--","--","100.0","No","","Y"
"Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second-Generation Cephalosporin","21","Medicare Part B Claims","Process","Y","","","1.3 - 88.45","88.46 - 98.52","98.53 - 99.99","--","--","--","--","100.0","No","","Y"
"Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow","67","QCDR Measure","Process","Y","","","9.68 - 12.76","12.77 - 25.57","25.58 - 99.99","--","--","--","--","100.0","No","","N"
"Pneumococcal Vaccination Status for Older Adults","111","eCQM","Process","Y","","","0.25 - 2.43","2.44 - 8.61","8.62 - 31.59","31.6 - 59.82","59.83 - 77.88","77.89 - 89.96","89.97 - 96.51",">= 96.52","No","","N"
"Pneumococcal Vaccination Status for Older Adults","111","Medicare Part B Claims","Process","Y","","","2.55 - 32.22","32.23 - 49.73","49.74 - 72.98","72.99 - 87.36","87.37 - 99.34","99.35 - 99.99","--","100.0","No","","N"
"Parkinson’s Disease: Cognitive Impairment or Dysfunction Assessment for Patients with Parkinson's Disease","291","QCDR Measure","Process","Y","","","1.79 - 8.92","8.93 - 12.57","12.58 - 34.71","34.72 - 97.29","97.3 - 99.99","--","--","100.0","No","","N"
"Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin With or Without Clavulanate Prescribed for Patients with Acute Bacterial Sinusitis (Appropriate Use)","332","QCDR Measure","Process","Y","","","18.88 - 38.68","38.69 - 47.05","47.06 - 61.06","61.07 - 86.37","86.38 - 97.37","97.38 - 99.99","--","100.0","No","","Y"
"Adult Sinusitis: Computerized Tomography (CT) for Acute Sinusitis (Overuse)","333","QCDR Measure","Efficiency and Cost/Resource Use","Y","","","37.7 - 13.0","12.99 - 6.85","6.84 - 1.46","1.45 - 0.01","--","--","--","0.0","No","","Y"
"Children Who Have Dental Decay or Cavities","378","eCQM","Outcome","Y","","","5.42 - 2.83","2.82 - 1.73","1.72 - 0.65","0.64 - 0.01","--","--","--","0.0","No","","Y"
"Non-Recommended Cervical Cancer Screening in Adolescent Females","443","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"HIV Screening","475","eCQM","Process","Y","","","0.12 - 0.15","0.16 - 0.18","0.19 - 1.86","1.87 - 7.8","7.81 - 99.99","--","--","100.0","No","","N"
"""Functional Status Change for Patients with Lower Leg, Foot or Ankle Impairments""","219","QCDR Measure","patientReportedOutcome","Y","","","67.86 - 76.18","76.19 - 87.49","87.5 - 94.38","94.39 - 97.75","97.76 - 99.99","--","--","100.0","No","","Y"
"Biopsy Follow-Up","265","QCDR Measure","Process","Y","","","0.57 - 3.52","3.53 - 22.44","22.45 - 90.36","90.37 - 99.99","--","--","--","100.0","No","","Y"
"Dementia: Cognitive Assessment","281","eCQM","Process","Y","","","0.66 - 1.88","1.89 - 3.69","3.7 - 10.23","10.24 - 31.71","31.72 - 67.56","67.57 - 91.04","91.05 - 97.91",">= 97.92","No","","N"
"Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery","304","","Patient Engagement/Experience","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Lung Cancer Reporting (Resection Specimens)","396","Medicare Part B Claims","Process","Y","","","95.24 - 97.05","97.06 - 99.99","--","--","--","--","--","100.0","No","","Y"
"Lung Cancer Reporting (Resection Specimens)","396","QCDR Measure","Process","Y","","","84.62 - 99.99","--","--","--","--","--","--","100.0","No","","Y"
"Anesthesiology Smoking Abstinence","404","QCDR Measure","Intermediate Outcome","Y","","","5.25 - 27.08","27.09 - 42.32","42.33 - 57.26","57.27 - 72.47","72.48 - 86.59","86.6 - 96.34","96.35 - 99.99","100.0","No","","Y"
"Skin Cancer: Biopsy Reporting Time – Pathologist to Clinician","440","QCDR Measure","Process","Y","","","53.85 - 90.47","90.48 - 94.63","94.64 - 99.16","99.17 - 99.99","--","--","--","100.0","No","","Y"
"Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis","116","QCDR Measure","Process","Y","","","10.87 - 30.76","30.77 - 47.82","47.83 - 68.41","68.42 - 93.21","93.22 - 98.93","98.94 - 99.99","--","100.0","No","","Y"
"""HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia, Gonorrhea, and Syphilis""","205","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Anastomotic Leak Intervention","354","QCDR Measure","Outcome","Y","","","86.49 - 40.49","40.48 - 6.53","6.52 - 2.54","2.53 - 0.01","--","--","--","0.0","No","","Y"
"Functional Status Assessment for Total Knee Replacement","375","eCQM","Process","Y","","","0.12 - 0.69","0.7 - 2.69","2.7 - 8.32","8.33 - 20.88","20.89 - 49.99","50.0 - 61.02","61.03 - 99.99","100.0","No","","Y"
"Pelvic Organ Prolapse: Preoperative Screening for Uterine Malignancy","429","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Leg Pain After Lumbar Discectomy/Laminectomy","461","","patientReportedOutcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Melanoma: Coordination of Care","138","QCDR Measure","Process","Y","","","2.24 - 9.51","9.52 - 32.15","32.16 - 86.24","86.25 - 99.99","--","--","--","100.0","No","","Y"
"Functional Status Change for Patients with Low Back Impairments","220","QCDR Measure","patientReportedOutcome","Y","","","12.68 - 65.51","65.52 - 87.99","88.0 - 92.61","92.62 - 97.29","97.3 - 99.99","--","--","100.0","No","","Y"
"Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI)","323","QCDR Measure","Efficiency and Cost/Resource Use","Y","","","1.9 - 0.51","0.5 - 0.16","0.15 - 0.01","--","--","--","--","0.0","No","","Y"
"Maternity Care: Elective Delivery or Early Induction Without Medical Indication at < 39 Weeks (Overuse)","335","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"""Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis on a Biological Immune Response Modifier""","337","QCDR Measure","Process","Y","","","4.08 - 18.3","18.31 - 37.64","37.65 - 76.71","76.72 - 94.5","94.51 - 99.99","--","--","100.0","No","","N"
"Total Knee Replacement: Venous Thromboembolic and Cardiovascular Risk Evaluation","351","QCDR Measure","Process","Y","","","2.35 - 25.24","25.25 - 84.96","84.97 - 99.99","--","--","--","--","100.0","No","","Y"
"Annual Hepatitis C Virus (HCV) Screening for Patients who are Active Injection Drug Users","387","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Opioid Therapy Follow-up Evaluation","408","QCDR Measure","Process","Y","","","0.33 - 1.89","1.9 - 18.54","18.55 - 85.05","85.06 - 99.96","99.97 - 99.99","--","--","100.0","No","","Y"
"Cardiac Tamponade and/or Pericardiocentesis Following Atrial Fibrillation Ablation","392","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Functional Status After Primary Total Knee Replacement","470","","patientReportedOutcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients","102","eCQM","Process","Y","","","71.43 - 71.9","71.91 - 78.56","78.57 - 96.54","96.55 - 99.99","--","--","--","100.0","No","","Y"
"Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery","191","eCQM","Outcome","Y","","","22.02 - 58.69","58.7 - 76.82","76.83 - 92.51","92.52 - 97.45","97.46 - 99.42","99.43 - 99.99","--","100.0","No","","Y"
"""Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home by Post-Operative Day #2)""","260","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Inflammatory Bowel Disease (IBD): Assessment of Hepatitis B Virus (HBV) Status Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy","275","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Dementia: Education and Support of Caregivers for Patients with Dementia","288","QCDR Measure","Process","Y","","","0.97 - 6.11","6.12 - 16.99","17.0 - 60.55","60.56 - 94.77","94.78 - 99.99","--","--","100.0","No","","Y"
"Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery","303","","patientReportedOutcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Chlamydia Screening for Women","310","eCQM","Process","Y","","","0.55 - 4.75","4.76 - 11.42","11.43 - 23.8","23.81 - 37.65","37.66 - 51.37","51.38 - 65.86","65.87 - 73.46",">= 73.47","No","","N"
"Follow-Up After Hospitalization for Mental Illness (FUH)","391","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Documentation of Signed Opioid Treatment Agreement","412","QCDR Measure","Process","Y","","","0.16 - 0.71","0.72 - 4.85","4.86 - 43.39","43.4 - 99.61","99.62 - 99.99","--","--","100.0","No","","Y"
"Oncology: Medical and Radiation – Pain Intensity Quantified","143","eCQM","Process","Y","","","2.33 - 8.88","8.89 - 35.82","35.83 - 84.49","84.5 - 96.56","96.57 - 99.4","99.41 - 99.99","--","100.0","No","","Y"
"Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #2)","259","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Appropriate Assessment of Retrievable Inferior Vena Cava (IVC) Filters for Removal","421","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Functional Status After Lumbar Discectomy/Laminectomy","471","","patientReportedOutcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Advance Care Plan","47","QCDR Measure","Process","Y","","","0.12 - 0.63","0.64 - 2.49","2.5 - 31.79","31.8 - 78.63","78.64 - 97.47","97.48 - 99.99","--","100.0","No","","Y"
"Advance Care Plan","47","Medicare Part B Claims","Process","Y","","","0.69 - 6.04","6.05 - 20.84","20.85 - 94.5","94.51 - 99.99","--","--","--","100.0","No","","Y"
"Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry","70","QCDR Measure","Process","Y","","","5.0 - 22.21","22.22 - 45.64","45.65 - 95.44","95.45 - 99.99","--","--","--","100.0","No","","N"
"Diabetes: Medical Attention for Nephropathy","119","eCQM","Process","Y","","","9.28 - 43.39","43.4 - 58.41","58.42 - 74.45","74.46 - 85.71","85.72 - 93.75","93.76 - 99.13","99.14 - 99.99","100.0","No","","N"
"""Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation""","126","QCDR Measure","Process","Y","","","0.44 - 9.34","9.35 - 31.24","31.25 - 68.85","68.86 - 94.86","94.87 - 99.99","--","--","100.0","No","","N"
"Cervical Cancer Screening","309","eCQM","Process","Y","","","0.28 - 1.91","1.92 - 4.81","4.82 - 14.83","14.84 - 32.21","32.22 - 50.47","50.48 - 67.58","67.59 - 78.56",">= 78.57","No","","N"
"Tobacco Use and Help with Quitting Among Adolescents","402","QCDR Measure","Process","Y","","","21.82 - 61.44","61.45 - 75.74","75.75 - 91.61","91.62 - 98.54","98.55 - 99.99","--","--","100.0","No","","N"
"Overuse of Imaging for the Evaluation of Primary Headache","419","QCDR Measure","Process","Y","","","96.43 - 62.23","62.22 - 50.58","50.57 - 20.84","20.83 - 5.99","5.98 - 1.4","1.39 - 0.01","--","0.0","No","","Y"
"Photodocumentation of Cecal Intubation","425","QCDR Measure","Process","Y","","","4.77 - 53.57","53.58 - 72.38","72.39 - 89.85","89.86 - 97.74","97.75 - 99.2","99.21 - 99.99","--","100.0","No","","N"
"Photodocumentation of Cecal Intubation","425","Medicare Part B Claims","Process","Y","","","91.03 - 94.58","94.59 - 97.29","97.3 - 99.14","99.15 - 99.99","--","--","--","100.0","No","","N"
"Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling","431","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Otitis Media with Effusion: Systemic Antimicrobials - Avoidance of Inappropriate Use","464","QCDR Measure","Process","Y","","","37.7 - 63.4","63.41 - 79.99","80.0 - 86.57","86.58 - 92.8","92.81 - 96.91","96.92 - 99.99","--","100.0","No","","Y"
"Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness","261","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Adult Sinusitis: Antibiotic Prescribed for Acute Viral Sinusitis (Overuse)","331","QCDR Measure","Process","Y","","","97.78 - 94.13","94.12 - 87.89","87.88 - 69.71","69.7 - 37.85","37.84 - 10.28","10.27 - 0.94","0.93 - 0.01","0.0","No","","Y"
"Amyotrophic Lateral Sclerosis (ALS) Patient Care Preferences","386","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Appropriate Follow-up Imaging for Incidental Abdominal Lesions","405","QCDR Measure","Process","Y","","","0.03 - 0.07","0.08 - 0.32","0.33 - 1.31","1.32 - 3.69","3.7 - 12.45","12.46 - 29.46","29.47 - 50.4",">= 50.41","No","","Y"
"Appropriate Follow-up Imaging for Incidental Abdominal Lesions","405","Medicare Part B Claims","Process","Y","","","0.05 - 0.42","0.43 - 1.27","1.28 - 3.84","3.85 - 9.51","9.52 - 18.36","18.37 - 35.7","35.71 - 81.24",">= 81.25","No","","Y"
"Back Pain After Lumbar Fusion","460","","patientReportedOutcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Unplanned Hospital Readmission within 30 Days of Principal Procedure","356","QCDR Measure","Outcome","Y","","","66.93 - 15.39","15.38 - 9.44","9.43 - 5.76","5.75 - 1.9","1.89 - 0.01","--","--","0.0","No","","Y"
"Back Pain After Lumbar Discectomy/Laminectomy","459","","patientReportedOutcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Communication with the Physician or Other Clinician Managing On-Going Care Post-Fracture for Men and Women Aged 50 Years and Older","24","QCDR Measure","Process","Y","","","0.19 - 2.34","2.35 - 2.87","2.88 - 33.89","33.9 - 82.87","82.88 - 96.57","96.58 - 99.99","--","100.0","No","","Y"
"Communication with the Physician or Other Clinician Managing On-Going Care Post-Fracture for Men and Women Aged 50 Years and Older","24","Medicare Part B Claims","Process","Y","","","33.33 - 54.04","54.05 - 74.99","75.0 - 92.3","92.31 - 99.99","--","--","--","100.0","No","","Y"
"Rheumatoid Arthritis (RA): Functional Status Assessment","178","QCDR Measure","Process","Y","","","1.33 - 20.86","20.87 - 43.36","43.37 - 86.43","86.44 - 97.85","97.86 - 99.99","--","--","100.0","No","","N"
"Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention","226","Medicare Part B Claims","Process","Y","","","8.7 - 34.88","34.89 - 57.15","57.16 - 89.24","89.25 - 99.99","--","--","--","100.0","No","","N"
"Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention","226","eCQM","Process","Y","","","1.67 - 5.7","5.71 - 9.67","9.68 - 20.24","20.25 - 44.91","44.92 - 83.32","83.33 - 98.45","98.46 - 99.99","100.0","No","","N"
"Radical Prostatectomy Pathology Reporting","250","Medicare Part B Claims","Process","Y","","","32.08 - 99.99","--","--","--","--","--","--","100.0","No","","N"
"Radical Prostatectomy Pathology Reporting","250","QCDR Measure","Process","Y","","","95.83 - 99.99","--","--","--","--","--","--","100.0","No","","N"
"Falls: Screening for Future Fall Risk","318","eCQM","Process","Y","","","0.14 - 0.97","0.98 - 3.95","3.96 - 27.42","27.43 - 66.12","66.13 - 90.71","90.72 - 98.18","98.19 - 99.52",">= 99.53","No","","Y"
"CAHPS for MIPs Clinician/Group Survey","321","","Patient Engagement/Experience","N","","","--","--","--","--","--","--","--","--","No","","Y"
"HIV Medical Visit Frequency","340","QCDR Measure","Process","Y","","","37.42 - 40.42","40.43 - 47.38","47.39 - 59.99","60.0 - 77.15","77.16 - 99.99","--","--","100.0","No","","Y"
"Lung Cancer Reporting (Biopsy/Cytology Specimens)","395","QCDR Measure","Process","Y","","","16.61 - 98.83","98.84 - 99.99","--","--","--","--","--","100.0","No","","Y"
"Lung Cancer Reporting (Biopsy/Cytology Specimens)","395","Medicare Part B Claims","Process","Y","","","78.79 - 95.99","96.0 - 97.61","97.62 - 99.99","--","--","--","--","100.0","No","","Y"
"Proportion of Patients Sustaining a Ureter Injury at the Time of Pelvic Organ Prolapse Repair","434","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Leg Pain After Lumbar Fusion","473","","patientReportedOutcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Coronary Artery Disease (CAD): Beta-Blocker Therapy – Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)","7","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High Risk Prostate Cancer","104","QCDR Measure","Process","Y","","","29.41 - 50.87","50.88 - 73.01","73.02 - 97.4","97.41 - 99.99","--","--","--","100.0","No","","N"
"Melanoma Reporting","397","QCDR Measure","Process","Y","","","22.73 - 91.53","91.54 - 97.13","97.14 - 99.99","--","--","--","--","100.0","No","","Y"
"Melanoma Reporting","397","Medicare Part B Claims","Process","Y","","","81.82 - 84.99","85.0 - 95.23","95.24 - 99.99","--","--","--","--","100.0","No","","Y"
"Adult Major Depressive Disorder (MDD): Suicide Risk Assessment","107","eCQM","Process","Y","","","0.03 - 0.34","0.35 - 0.74","0.75 - 3.0","3.01 - 20.78","20.79 - 64.28","64.29 - 92.61","92.62 - 97.21",">= 97.22","No","","N"
"Percentage of Patients Who Died from Cancer Receiving Chemotherapy in the Last 14 Days of Life (lower score – better)","453","QCDR Measure","Process","Y","","","35.14 - 26.54","26.53 - 23.09","23.08 - 16.68","16.67 - 11.64","11.63 - 7.53","7.52 - 4.01","4.0 - 1.6","<= 1.59","No","","Y"
"Continuity of Pharmacotherapy for Opioid Use Disorder (OUD)","468","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation","12","eCQM","Process","Y","","","4.85 - 42.04","42.05 - 70.06","70.07 - 86.72","86.73 - 95.16","95.17 - 98.84","98.85 - 99.99","--","100.0","No","","N"
"Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation","12","Medicare Part B Claims","Process","Y","","","61.39 - 89.99","90.0 - 97.13","97.14 - 99.99","--","--","--","--","100.0","No","","N"
"Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation","12","QCDR Measure","Process","Y","","","62.5 - 84.76","84.77 - 91.1","91.11 - 97.39","97.4 - 99.99","--","--","--","100.0","No","","N"
"Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections","76","QCDR Measure","Process","Y","","","34.38 - 71.63","71.64 - 88.72","88.73 - 98.54","98.55 - 99.99","--","--","--","100.0","No","","Y"
"Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections","76","Medicare Part B Claims","Process","Y","","","2.5 - 57.77","57.78 - 93.93","93.94 - 99.99","--","--","--","--","100.0","No","","Y"
"Diabetes: Eye Exam","117","eCQM","Process","Y","","","0.48 - 2.32","2.33 - 5.4","5.41 - 18.46","18.47 - 55.41","55.42 - 98.29","98.3 - 99.99","--","100.0","No","","N"
"Diabetes: Eye Exam","117","Medicare Part B Claims","Process","Y","","","8.22 - 58.88","58.89 - 86.61","86.62 - 99.94","99.95 - 99.99","--","--","--","100.0","No","","N"
"Rheumatoid Arthritis (RA): Glucocorticoid Management","180","QCDR Measure","Process","Y","","","0.58 - 60.3","60.31 - 87.57","87.58 - 99.49","99.5 - 99.99","--","--","--","100.0","No","","N"
"Elder Maltreatment Screen and Follow-Up Plan","181","Medicare Part B Claims","Process","Y","","","0.08 - 0.45","0.46 - 11.07","11.08 - 99.54","99.55 - 99.99","--","--","--","100.0","No","","Y"
"Elder Maltreatment Screen and Follow-Up Plan","181","QCDR Measure","Process","Y","","","3.02 - 20.82","20.83 - 33.32","33.33 - 72.29","72.3 - 96.01","96.02 - 99.99","--","--","100.0","No","","Y"
"Use of High-Risk Medications in Older Adults","238","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)","8","eCQM","Process","Y","","","42.86 - 75.31","75.32 - 81.81","81.82 - 90.9","90.91 - 96.14","96.15 - 99.99","--","--","100.0","No","","N"
"Functional Status Change for Patients with Hip Impairments","218","QCDR Measure","patientReportedOutcome","Y","","","13.44 - 87.17","87.18 - 90.47","90.48 - 94.57","94.58 - 99.78","99.79 - 99.99","--","--","100.0","No","","Y"
"Sentinel Lymph Node Biopsy for Invasive Breast Cancer","264","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Hepatitis C: Discussion and Shared Decision Making Surrounding Treatment Options","390","QCDR Measure","Process","Y","","","1.55 - 7.68","7.69 - 7.68","7.69 - 28.94","28.95 - 90.47","90.48 - 99.99","--","--","100.0","No","","Y"
"Door to Puncture Time for Endovascular Stroke Treatment","413","","Intermediate Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Multimodal Pain Management","477","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Functional Status Change for Patients with Neck Impairments","478","","patientReportedOutcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Screening for Osteoporosis for Women Aged 65-85 Years of Age","39","QCDR Measure","Process","Y","","","0.3 - 1.11","1.12 - 2.7","2.71 - 19.48","19.49 - 50.99","51.0 - 72.87","72.88 - 90.51","90.52 - 96.71",">= 96.72","No","","N"
"Screening for Osteoporosis for Women Aged 65-85 Years of Age","39","Medicare Part B Claims","Process","Y","","","1.93 - 10.55","10.56 - 18.36","18.37 - 42.65","42.66 - 65.37","65.38 - 91.94","91.95 - 99.99","--","100.0","No","","N"
"Chronic Obstructive Pulmonary Disease (COPD): Long-Acting Inhaled Bronchodilator Therapy","52","QCDR Measure","Process","Y","","","37.3 - 61.44","61.45 - 72.59","72.6 - 88.39","88.4 - 99.47","99.48 - 99.99","--","--","100.0","No","","N"
"Chronic Obstructive Pulmonary Disease (COPD): Long-Acting Inhaled Bronchodilator Therapy","52","Medicare Part B Claims","Process","Y","","","85.71 - 94.58","94.59 - 96.1","96.11 - 99.87","99.88 - 99.99","--","--","--","100.0","No","","N"
"Radiology: Stenosis Measurement in Carotid Imaging Reports","195","QCDR Measure","Process","Y","","","37.21 - 87.96","87.97 - 95.87","95.88 - 99.61","99.62 - 99.99","--","--","--","100.0","No","","N"
"Radiology: Stenosis Measurement in Carotid Imaging Reports","195","Medicare Part B Claims","Process","Y","","","28.72 - 74.99","75.0 - 89.18","89.19 - 98.75","98.76 - 99.99","--","--","--","100.0","No","","N"
"Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain","254","QCDR Measure","Process","Y","","","58.54 - 76.63","76.64 - 81.81","81.82 - 90.62","90.63 - 96.76","96.77 - 99.52","99.53 - 99.99","--","100.0","No","","N"
"Depression Remission at Twelve Months","370","eCQM","Outcome","Y","","","0.64 - 1.4","1.41 - 2.28","2.29 - 4.18","4.19 - 7.45","7.46 - 12.81","12.82 - 22.65","22.66 - 32.55",">= 32.56","No","","Y"
"Immunizations for Adolescents","394","QCDR Measure","Process","Y","","","1.04 - 1.04","1.05 - 1.7","1.71 - 7.13","7.14 - 20.82","20.83 - 30.42","30.43 - 42.85","42.86 - 58.32",">= 58.33","No","","N"
"Percentage of Patients Who Died from Cancer Admitted to Hospice for Less than 3 days (lower score – better)","457","QCDR Measure","Outcome","Y","","","83.33 - 23.85","23.84 - 16.01","16.0 - 10.8","10.79 - 6.99","6.98 - 2.6","2.59 - 0.01","--","0.0","No","","Y"
"Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy","462","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care","19","Medicare Part B Claims","Process","Y","","","80.18 - 97.36","97.37 - 99.99","--","--","--","--","--","100.0","No","","Y"
"Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care","19","eCQM","Process","Y","","","3.23 - 20.5","20.51 - 37.6","37.61 - 64.99","65.0 - 85.19","85.2 - 96.09","96.1 - 99.99","--","100.0","No","","Y"
"""Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear""","127","QCDR Measure","Process","Y","","","0.44 - 8.63","8.64 - 27.06","27.07 - 67.2","67.21 - 94.34","94.35 - 99.99","--","--","100.0","No","","N"
"Falls: Risk Assessment","154","Medicare Part B Claims","Process","Y","","","10.53 - 65.84","65.85 - 85.95","85.96 - 99.99","--","--","--","--","100.0","No","","Y"
"Falls: Risk Assessment","154","QCDR Measure","Process","Y","","","1.83 - 29.2","29.21 - 64.51","64.52 - 93.39","93.4 - 99.99","--","--","--","100.0","No","","Y"
"Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low-Risk Surgery Patients","322","QCDR Measure","Efficiency and Cost/Resource Use","Y","","","16.67 - 7.29","7.28 - 3.62","3.61 - 0.01","--","--","--","--","0.0","No","","Y"
"Implantable Cardioverter-Defibrillator (ICD) Complications Rate","348","","Outcome","N","","","--","--","--","--","--","--","--","--","No","","Y"
"Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines","364","QCDR Measure","Process","Y","","","51.81 - 67.78","67.79 - 87.87","87.88 - 97.26","97.27 - 99.99","--","--","--","100.0","No","","Y"
"""Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists""","379","eCQM","Process","Y","","","0.0 - 0.01","0.02 - 0.04","0.05 - 0.37","0.38 - 2.1","2.11 - 6.6","6.61 - 13.41","13.42 - 16.86",">= 16.87","No","","N"
"Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis","401","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
"Appropriate Treatment for Patients with Stage I (T1c) - III HER2 Positive Breast Cancer","450","","Process","N","","","--","--","--","--","--","--","--","--","No","","Y"
"RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy","451","","Process","N","","","--","--","--","--","--","--","--","--","No","","N"
